Serbia Offers Investors More Time to Bid for Galenika Drug Maker

Serbia gave potential investors two more weeks to make offers for Galenika AD, an unprofitable drugmaker, as the government seeks to turn around money-losing state enterprises.

International pharmaceutical companies will have until April 1, instead of an original March 18 deadline, to submit letters of intent, according to the announcement the Belgrade- based Finance Ministry posted on its website.

Serbia invited companies active in the pharmaceuticals industry over the past five years and with operating revenue of more than 200 million euros ($267 million) in 2011, on Jan. 15 to submit their own proposals for a “privatization model” for Galenika.

To contact the reporter on this story: Gordana Filipovic in Belgrade at gfilipovic@bloomberg.net

To contact the editor responsible for this story: James M. Gomez at jagomez@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.